Special Issue

Cytokines in Clinical Cancer Immunotherapy

Message from the Guest Editors

The application of immunotherapy in clinical practice has significantly benefited cancer patients, particularly those with advanced disease. However, not all patients respond to immunotherapy. In combination with other regimens (e.g., chemotherapy, targeted therapy, and radiotherapy), improvement in patient survival suggests that interactions among immune cells, cancer cells, and microenvironments exist. Obtaining a better understanding of the potential mechanisms underlying these interactions, identifying the factors that affect these interactions and the efficacy of immunotherapy, evaluating the efficacy of combinations of different regimens, and identifying predictive and prognostic markers may help us to design better strategies for use in treatment and clinical practice. Current cancer immunotherapies include immune checkpoint inhibitors (ICIs), adoptive cell therapies (tumor-infiltrating lymphocytes (TILs), engineered T cell receptor therapy (TCR-T), CAR T cell therapy, and Natural Killer cell therapy), monoclonal antibodies, oncolytic virus therapy, cancer vaccines, and immune system modulators such as interleukins (IL) and interferons (IFN).

Guest Editors

Dr. Wenxue Ma

Department of Medicine, Moores Cancer Center & Sanford Stem Cell Clinical Center, University of California San Diego, La Jolla, CA, USA

Dr. Lingeng Lu

Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale Cancer Center, Yale University, New Haven, CT, USA

Deadline for manuscript submissions

closed (30 April 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed

mdpi.com/si/111848

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)